These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis. Fairweather M; Balachandran VP; Li GZ; Bertagnolli MM; Antonescu C; Tap W; Singer S; DeMatteo RP; Raut CP Ann Surg; 2018 Aug; 268(2):296-302. PubMed ID: 28448384 [TBL] [Abstract][Full Text] [Related]
6. Cytoreductive surgery for metastatic gastrointestinal stromal tumors followed by sunitinib compared to followed by imatinib-a multi-center cohort study. Zhang X; Zhou Y; Wu X; Nie M; Zhang B; Zhou Y; Sun L; Liu Z; Liu X; Kou Y; Wang Y; Zhang Y; Hao C; Shen L; Li J Eur J Surg Oncol; 2019 Mar; 45(3):318-323. PubMed ID: 30145000 [TBL] [Abstract][Full Text] [Related]
7. Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. Chen YY; Yeh CN; Cheng CT; Chen TW; Rau KM; Jan YY; Chen MF World J Gastroenterol; 2011 Apr; 17(16):2113-9. PubMed ID: 21547131 [TBL] [Abstract][Full Text] [Related]
8. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience. Kim JH; Ryu MH; Yoo C; Chae H; Na H; Beck M; Kim BS; Yoo MW; Yook JH; Kim BS; Kim KH; Kim CW; Kang YK Cancer Med; 2019 Mar; 8(3):1034-1043. PubMed ID: 30693663 [TBL] [Abstract][Full Text] [Related]
10. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors. Keung EZ; Fairweather M; Raut CP Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287 [TBL] [Abstract][Full Text] [Related]
12. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. Ruka W; Rutkowski P; Szawłowski A; Nowecki Z; Debiec-Rychter M; Grzesiakowska U; Dziewirski W; Siedlecki JA; Michej W Eur J Surg Oncol; 2009 Jan; 35(1):87-91. PubMed ID: 18289826 [TBL] [Abstract][Full Text] [Related]
13. [The importance of mutational status in prognosis and therapy of GIST]. Comandone A; Boglione A Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775 [TBL] [Abstract][Full Text] [Related]
14. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Vincenzi B; Nannini M; Fumagalli E; Bronte G; Frezza AM; De Lisi D; Spalato Ceruso M; Santini D; Badalamenti G; Pantaleo MA; Russo A; Dei Tos AP; Casali P; Tonini G Oncotarget; 2016 Oct; 7(43):69412-69419. PubMed ID: 26416414 [TBL] [Abstract][Full Text] [Related]
15. Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors. Zaydfudim V; Okuno SH; Que FG; Nagorney DM; Donohue JH J Surg Res; 2012 Oct; 177(2):248-54. PubMed ID: 22831567 [TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). Bauer S; Rutkowski P; Hohenberger P; Miceli R; Fumagalli E; Siedlecki JA; Nguyen BP; Kerst M; Fiore M; Nyckowski P; Hoiczyk M; Cats A; Casali PG; Treckmann J; van Coevorden F; Gronchi A Eur J Surg Oncol; 2014 Apr; 40(4):412-9. PubMed ID: 24491288 [TBL] [Abstract][Full Text] [Related]
17. [Changes of diagnosis and treatment for gastrointestinal stromal tumors during a 18-year period in four medical centers of China]. Qiu H; Zhang P; Feng X; Chen T; Sun X; Yu J; Chen Z; Li Y; Tao K; Li G; Zhou Z Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1265-1270. PubMed ID: 27928797 [TBL] [Abstract][Full Text] [Related]
18. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087 [TBL] [Abstract][Full Text] [Related]
19. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance. Patel S Cancer Treat Rev; 2012 Aug; 38(5):467-72. PubMed ID: 22035971 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. Blesius A; Cassier PA; Bertucci F; Fayette J; Ray-Coquard I; Bui B; Adenis A; Rios M; Cupissol D; Pérol D; Blay JY; Le Cesne A BMC Cancer; 2011 Feb; 11():72. PubMed ID: 21324142 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]